Michael K Hehir (Michael Hehir)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Replacement Therapy

Myasthenia Gravis

End Stage Renal Disease

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Kelly Graham Gwathmey, Huanghe Ding, Michael K Hehir, Nicholas J Silvestri
How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis? Muscle & nerve 69 (4) (2024)
Kelly Graham Gwathmey, Huanghe Ding, Michael K Hehir, Nicholas J Silvestri
How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis? Muscle & nerve 69 (4) (2024)
Kelly Graham Gwathmey, Huanghe Ding, Michael K Hehir, Nicholas J Silvestri
How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis? Muscle & nerve (2024)
Michael K Hehir, Mark Conaway, Avery B St Sauveur, Kendall Feb, Noah Allan Kolb, Waqar Waheed, Brendan L McNeish, Nicole Tweedy, Ted M Burns
Measuring treatment adverse event burden in myasthenia gravis: Single-center prospective evaluation utilizing the Adverse Event Unit (AEU). Muscle & nerve (2023)
Ikjae Lee, Jesse D Schold, Michael K Hehir, Benjamin Claytor, Nicholas J Silvestri, Yuebing Li
Re: Diagnosing myasthenia gravis in older patients: Comments and observations. Muscle & nerve 66 (4) (2022)
Michael K Hehir, Mark Conaway, Eric M Clark, Denise B Aronzon, Noah Kolb, Amanda Kolb, Katherine Ruzhansky, Reza Sadjadi, Eduardo A De Sousa, Ted M Burns
The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events. PloS one 17 (2) (2022)